Zanamivir

Y. Vivian Tsai, Pharm.D., Paul G. Auwaerter, M.D.

INDICATIONS

INDICATIONS

INDICATIONS

FDA

FDA

FDA

  • Uncomplicated acute illness due to influenza A and B infection (patients > 7 yrs of age with < 48hr symptoms).
    • Clinical benefit is best established when treatment is initiated within 48 hours of symptom onset in uncomplicated influenza.
    • It is FDA-approved for treatment in patients aged 7 years and older, but use is limited by inhaled administration and is not recommended in patients with asthma, COPD, or other underlying airway disease.
  • Influenza prophylaxis in those 5 years of age or older.
    • Not proven effective for prophylaxis in nursing home residents.

NON-FDA APPROVED USES

NON-FDA APPROVED USES

NON-FDA APPROVED USES

  • Bronchitis, acute, uncomplicated (due to influenza)
  • Chronic bronchitis, acute exacerbations (due to influenza)
  • Influenza, avian

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2026 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.